Congress targets deceptive abortion-clinic ads to protect access

What it does

This bill makes it illegal for any organization—including crisis pregnancy centers (CPCs)—to advertise falsely about reproductive health services they offer. Specifically, it prohibits deceptive ads claiming to offer abortion, contraception, or referrals for these services, or claiming to employ licensed medical personnel, when they do not. The Federal Trade Commission (FTC) enforces the rule through civil penalties up to $100,000 per violation or 50% of the violator's parent company revenue, and can sue for injunctions, damages, and restitution.

Why we flagged it

The bill's operative mechanism is a straightforward FTC enforcement action against deceptive advertising in a specific sector (reproductive health services). It does not restrict speech or advocacy; it prohibits false factual claims about services offered and personnel employed—a traditional consumer-protection function.

What the text implies

• The bill grants the FTC exclusive enforcement authority and bars private litigation, concentrating power in a single agency and potentially limiting individual remedies for consumers harmed by deceptive practices.
• The definition of 'abortion services' is broad ('any medical or non-medical service related to or provided in conjunction with an abortion') and may create ambiguity in enforcement—e.g., whether counseling, ultrasounds, or referrals count as 'abortion services' for purposes of the prohibition.
• CPCs are the primary target, but the bill applies to 'any person,' potentially capturing mainstream healthcare providers, pharmacies, or telehealth platforms if they make false claims about abortion or contraception availability.
• The bill does not address CPCs' underlying operations (counseling, ultrasounds, etc.); it only restricts false advertising. CPCs may continue operating and providing services; they simply cannot lie about what they offer or who staffs them.
• Enforcement depends on FTC resources and political will; a hostile administration could deprioritize enforcement, leaving the statutory prohibition largely unenforced.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens—particularly low-income women and women of color in underserved areas—gain protection against deceptive advertising that delays or prevents access to time-sensitive reproductive health care. The bill targets organizations that deliberately mislead vulnerable people about services and privacy practices, a documented harm. The enforcement mechanism is narrow (false advertising only) and does not restrict anyone's right to operate or advocate.

Named in the bill

Federal Trade Commission (FTC), Crisis Pregnancy Centers (CPCs), Abortion clinics, Reproductive health care providers, Low-income women, Women of color, Transgender and gender nonconforming individuals

Where it stands

86 cosponsors: 86 Democrats.

• Jan 31, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 31, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,759,355 in lobbying spend. A filing names 48 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Suzanne Bonamici, the sponsor, reported $461,650 in PAC receipts in the 2026 cycle.

• American Academy of Family Physicians — $1,715,904 on 2 filings
• Power to Decide — $33,451 on 2 filings
• National Council of Jewish Women — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.